Manara - Qatar Research Repository
Browse

Could the New BA.2.75 Sub-Variant Cause the Emergence of a Global Epidemic of COVID-19? A Scoping Review

Download (6.67 MB)
journal contribution
submitted on 2025-05-21, 08:53 and posted on 2025-05-21, 08:54 authored by Nour Shaheen, Abdelrahman Mohamed, Almoatazbellah Attalla, Rehab Adel Diab, Sarya Swed, Abdulqadir J Nashwan, Ala’ Abdala Rababah, Mahmoud Tarek Hefnawy, Youssef Soliman, Omar Ahmed Abdelwahab, Mariam Tarek Desouki, Abdulrhman Khaity, Ahmed Shaheen, Abdelraouf Ramadan, Mostafa Meshref

With over 58 million cases and 6 million deaths by August 2022, the Coronavirus disease 2019 (COVID-19), causing severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2), has had an insurmountable impact on the world’s population. This is one of the worst health crises since 1918’s influenza pandemic. There are four subvariants of Omicron; BA.1, BA.1.1, BA.2 and BA.3. As a result of new mutations in its spike protein, most of which occur in its receptor binding site, the Omicron variant appears to be more transmissible and less resistant to vaccination and antibody response. Understanding Omicron’s virology and mutations is essential to developing diagnostic and therapeutic methods. A thorough assessment of control measures, as well as timely adjustment of control measures, requires addressing such issues as re-infection risk, vaccine response, booster vaccine doses, and the increased rate of Omicron infections. This review article aims to look at the current information about the different types of SARs-CoV-2, focusing on the new subtype BA.2.75.

Other Information

Published in: Infection and Drug Resistance
License: https://creativecommons.org/licenses/by/4.0/
See article on publisher's website: https://dx.doi.org/10.2147/idr.s387551

Funding

Open Access funding provided by the Qatar National Library.

History

Language

  • English

Publisher

Dove Medical Press

Publication Year

  • 2022

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License.

Institution affiliated with

  • Hamad Medical Corporation

Usage metrics

    Hamad Medical Corporation

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC